35.90 -0.56 (-1.54%)
Pre-Market: 8:20AM EST
|Bid||35.80 x 800|
|Ask||35.74 x 800|
|Day's Range||35.84 - 37.60|
|52 Week Range||25.04 - 43.16|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2020 - May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.50|
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
QIAGEN (QGEN) expands the molecular testing portfolio by shipping QIAstat-Dx Respiratory 2019-nCoV Panel to China for faster detection of coronavirus SARS-CoV-2.
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Investors in QIAGEN N.V. (NYSE:QGEN) had a good week, as its shares rose 5.8% to close at US$35.75 following the...
NEW YORK, NY / ACCESSWIRE / February 5, 2020 / QIAGEN NV (NYSE:QGEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on February 5, 2020 at 9:00 AM Eastern Time. ...
Qiagen (QGEN) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN launches FFPE and Liquid Biopsy PIK3CA diagnostics in Europe to enhance precision medicine in advanced breast cancer
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN builds on global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer
Calibre Scientific is pleased to announce that it has completed the acquisition of the NeXtal Biotechnologies line of structural biology products from Qiagen NV (QGEN). NeXtal specializes in the production of unique screens and plates for protein crystallization, an important step in the complex process of structural biology studies and structure-based drug design. NeXtal’s products include a comprehensive suite of reliable crystallization screens and proprietary EasyXtal crystallization plates that are currently sold into academic, biotechnology, and pharmaceutical markets.
Benzinga's PreMarket Prep show resumed Thursday after a pause for the Christmas holiday. As always, there were a few market movers to cover and two informative interviews. Qiagen Decides Not To Sell When ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...
Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. Qiagen announced last month that it had received "several" entreaties to acquire the molecular-diagnostics specialist, and were exploring the opportunities. Shares, which had been hit hard by a CEO departure and China-related concerns, rebounded on that news. After the shortened Christmas Eve trading session ended, though, Qiagen announced that its management and supervisory boards had opted against a sale and terminated all discussions because "the alternatives to the stand-alone business plan prospects were not compelling." Shares closed Tuesday with a 0.8% increase at $41.47, then dove to less than $31 in after-hours trading following the announcement.